等待開盤 07-06 09:30:00 美东时间
+0.330
+1.37%
Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today
05-29 19:34
Adaptive Biotech says clonoSEQ MRD test features in 33 ASCO, EHA presentations Adaptive Biotechnologies flagged clonoSEQ MRD test data across 33 presentations scheduled for ASCO May 29–June 3, 2026, and EHA June 11–14, 2026. Presentations are set to position clonoSEQ as a decision-support tool for r
05-29 19:30
BRIEF-Stephen Smith And Smith Financial Corporation Acquire Minority Stake In The Economist Group April 24 (Reuters) - THE ECONOMIST GROUP: STEPHEN SMITH AND SMITH FINANCIAL CORPORATION ACQUIRE MINORITY STAKE IN THE ECONOMIST GROUP THE ECONOMIST GROUP: FINANCIAL TERMS OF TRANSACTION HAVE NOT BEEN DI
04-24 17:46
https://pco.gov.ph/news_releases/govt-orders-meta-platforms-inc-to-curb-all-fake-news-warns-of-legal-action/
04-13 21:49
BRIEF-American Express Chairman And CEO Stephen J. Squeri Highlights The Company’S 2025 Performance And Position Of Strength In An Ai-Powered World In Letter To Shareholders American Express Co AXP.N : AMERICAN EXPRESS CHAIRMAN AND CEO STEPHEN J. SQUERI HIGHLIGHTS THE COMPANY’S 2025 PERFORMANCE AND
03-25 20:30
BRIEF-Unitedhealth - Amends Stock Option For Stephen Hemsley - SEC Filing Feb 25 (Reuters) - UnitedHealth Group Inc UNH.N : UNITEDHEALTH - AMENDS STOCK OPTION FOR STEPHEN HEMSLEY - SEC FILING UNITEDHEALTH - AMENDMENT ADDS TWO-YEAR SHARE HOLDING REQUIREMENT UNTIL MAY 2030 - SEC FILING Source text: []
02-25 19:25
BRIEF-RCL Says Samuel Minzberg To Become Board Chair Feb 19 (Reuters) - Reitmans Canada Ltd RETa.V : RCL ANNOUNCES BOARD LEADERSHIP TRANSITION REITMANS CANADA LTD - STEPHEN REITMAN TRANSITIONS TO BOARD DIRECTOR AND CHAIRMAN EMERITUS REITMANS CANADA LTD: SAMUEL MINZBERG TO BECOME BOARD CHAIR Source t
02-20 06:55
BRIEF-Nektar Therapeutics Announces Research Collaboration With Ucsf And Dr. Stephen Hauser For Nktr-0165 Feb 17 (Reuters) - Nektar Therapeutics NKTR.O : NEKTAR THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH UCSF AND DR. STEPHEN HAUSER FOR NKTR-0165, A TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) AN
02-17 20:27
BRIEF-Av Welcomes Stephen Voline As Senior Director, Washington Operations Feb 11 (Reuters) - AeroVironment Inc AVAV.O : AV WELCOMES STEPHEN VOLINE AS SENIOR DIRECTOR, WASHINGTON OPERATIONS Source text: ID:nBwRqZ41a Further company coverage: AVAV.O (( Reuters.Briefs@thomsonreuters.com ;))
02-11 20:45